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Abstract
Gonorrhoea is a sexually transmitted infection with major public
health implications and Neisseria gonorrhoeae has developed
resistance to all antimicrobials introduced for treatment.
Enhanced surveillance of antimicrobial resistance in N. gonorrhoeae
is crucial globally. This is the ﬁrst internationally reported
antimicrobial resistance data for N. gonorrhoeae from Estonia (44
isolates cultured in 2009–2013). A high prevalence of resistance
was observed for azithromycin, ciproﬂoxacin and tetracycline.
One and two isolates with resistance and decreased susceptibility
to the last remaining ﬁrst-line treatment option ceftriaxone,
respectively, were identiﬁed. It is crucial to implement surveillance
of gonococcal antimicrobial resistance (ideally also treatment
failures) in Estonia.
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Gonorrhoea is a sexually transmitted infection with major
public health implications. The WHO estimated that 106
million new cases of gonorrhoea occurred among adults
worldwide in 2008, which represented a 21% increase
compared with 2005 [1]. Gonorrhoea, including its severe
complications, results in substantial morbidity and economic
costs globally. In Estonia, the reported annual incidence (cases
per 100 000 population) of gonorrhoea showed an all-time
high in 1993 (233.9). The incidence subsequently decreased
annually to 8.8 in 2010; although there was a slight increase to
12.4 in 2011, which was the fourth highest incidence in the
European Union in 2011 [2]. The ﬁrst-line empiric treatment
of gonorrhoea in Estonia is ceftriaxone (250 mg intramuscu-
larly) [3]; however, in practice a variety of antimicrobials can
be used (particularly among private practitioners), e.g. ce-
ﬁxime, azithromycin, ﬂuoroquinolones or tetracyclines. The
emergence of treatment failures to the last remaining option
for treatment, i.e. ceftriaxone, [4–9] and extensively drug
resistant Neisseria gonorrhoeae strains [9–11] has placed
antimicrobial resistance (AMR) surveillance as an essential
key priority nationally and internationally; however, no AMR
data for N. gonorrhoeae has ever been internationally reported
from Estonia.
In this study, we investigated the AMR to previously and
currently recommended treatment options and genotypic
characteristics of N. gonorrhoeae isolates in 2009–2013 in
Estonia.
Forty-four clinical N. gonorrhoeae isolates were tested from
2009 (n = 5), 2010 (n = 6), 2011 (n = 5), 2012 (n = 15) and
2013 (n = 13). The isolates were cultured from mainly
symptomatic gonorrhoea patients (17 women, 26 men and 1
unknown) attending different dermatovenereological clinics in
Estonia. Mean age for the women was 25 years (median
25 years; range 16–40 years) and for the men 28 years
(median 29 years; range 22–40 years). Twenty-ﬁve (56.8%)
isolates were obtained from specimens from male urethra, 17
(38.6%) from cervix, one (2.3%) from male rectum, and one
unknown (2.3%). All isolates were cultured, species was
veriﬁed and samples were preserved as previously described
[12]. The MICs (mg/L) of ceftriaxone, ceﬁxime, azithromycin,
spectinomycin, ciproﬂoxacin, tetracycline and gentamicin were
analysed using the Etest method, according to the instructions
from the manufacturer (BioMerieux AB, Solna, Sweden). All
results were interpreted using whole MIC dilutions and
breakpoints for susceptibility (S) and resistance (R) according
to the European Committee on Antimicrobial Susceptibility
Testing (EUCAST: www.eucast.org). Furthermore, isolates
with a cephalosporin MIC of >0.064 to 0.125 mg/L have
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resulted in treatment failures [4–8] and, accordingly, these
isolates were considered to have a decreased susceptibility to
ceﬁxime and ceftriaxone. The penA gene, encoding the lethal
cephalosporin target penicillin-binding protein 2, was
sequenced as previously described [13]. For gentamicin, no
breakpoints are stated by any organization. b-lactamase
production was identiﬁed using nitroceﬁn solution. Bacterial
DNA was isolated using the NorDiag Bullet instrument with
the BUGS’n BEADSTM STI-fast kit (NorDiag ASA Company,
Oslo, Norway), according to the instructions from the
manufacturer. Genotyping by N. gonorrhoeae multiantigen
sequence typing (NG-MAST) was performed as previously
described [13,14]. The penA gene, the main cephalosporin-
resistance determinant, was sequenced in isolates displaying
decreased susceptibility or resistance to ceftriaxone and
categorized as previously described [9,13]. The 2008 WHO
N. gonorrhoeae reference strains [13] were used for quality
control in all phenotypic and molecular characterization.
The results of the AMR testing of all isolates are summa-
rized in Table 1. Brieﬂy, the overall proportions of isolates
with resistance were as follows: ceftriaxone 2.3%, azithromy-
cin 22.7%, ciproﬂoxacin 27.3% and tetracycline 34.1%. No
isolates resistant to ceﬁxime or spectinomycin were identiﬁed,
and the MICs of gentamicin were low (MIC range 2–8 mg/L).
Eight (18.2%) of the isolates showed multidrug resistance, i.e.
resistance to azithromycin, ciproﬂoxacin and tetracycline.
Seven (15.9%) of the isolates were b-lactamase producing.
One (2.3%) isolate with resistance to ceftriaxone
(MIC = 0.25 mg/L) and two (4.5%) isolates displaying
decreased susceptibility to ceftriaxone (MIC = 0.125 mg/L
[12,15]) were identiﬁed. All these three isolates possessed a
penA mosaic allele XXXIV [9], explaining the enhanced MICs of
ceftriaxone. Furthermore, two of these isolates had a
decreased susceptibility also to ceﬁxime (MIC = 0.125 mg/L),
while the third isolate was susceptible to ceﬁxime
(MIC = 0.032 mg/L). No additional isolates displayed a
decreased susceptibility to ceﬁxime. Among the 44 isolates,
18 different NG-MAST sequence types (STs) were identiﬁed,
of which nine (50%) STs have not been previously described
(Table 2). Nine (50%) of the STs were represented by more
than one isolate. ST1241 was the most prevalent genotype,
and all ST1241 isolates (n = 14) were susceptible to all tested
antimicrobials. Isolates of the second most prevalent genotype,
ST2212 (n = 6), were resistant to azithromycin, ciproﬂoxacin
and tetracycline, and one of these ST2212 isolates also showed
a decreased susceptibility (MIC = 0.125 mg/L) to ceftriaxone
and ceﬁxime (Table 2).
In the present study, the susceptibility to previously and
currently recommended antimicrobials for treatment of gon-
orrhoea was investigated in N. gonorrhoeae isolated in 2009–
2013 in Estonia. Despite the global concern over extensively
drug resistant gonorrhoea and the possibility of untreatable
gonorrhoea in the future [9], this is the ﬁrst internationally
reported AMR data for N. gonorrhoeae from Estonia. A high
prevalence of resistance was observed for azithromycin
(22.7%), ciproﬂoxacin (27.3%) and tetracycline (34.1%), but
no resistance to ceﬁxime or spectinomycin was found
(Table 1). Worryingly, one (2.3%) and two (4.5%) isolates
with resistance and decreased susceptibility, respectively, to
the last remaining ﬁrst-line treatment option ceftriaxone were
TABLE 1. Antimicrobial susceptibility of 44 Neisseria gonor-
rhoeae isolates from Estonia, 2009–2013
Antimicrobial
breakpoints (mg/L)a S (%) I (%) R (%)
Ceftriaxone (S ≤ 0.125, R >0.125) 43 (97.7) NA 1 (2.3)
Ceﬁxime (S ≤0.125, R >0.125) 44 (100) NA 0
Spectinomycin (S ≤64, R >64) 44 (100) NA 0
Azithromycin (S ≤0.25, R >0.5) 24 (54.5) 10 (22.7) 10 (22.7)
Ciproﬂoxacin (S ≤0.032, R >0.064) 32 (72.7) 0 12 (27.3)
Tetracycline (S ≤0.5, R >1.0) 27 (61.4) 2 (4.5) 15 (34.1)
Gentamicinb MIC range: 2–8 mg/L; MIC50: 4 mg/L;
and MIC90: 4 mg/L
b-lactamase production 2009: 0 (0%); 2010: 1 (16.7%);
2011: 2 (40.0%); 2012: 4 (26.7%);
and 2013: 0 (0%)
S, susceptible; I, intermediate susceptible; R, resistant; NA, not applicable.
aBreakpoints according to The European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST; www.eucast.org).
bBreakpoints not stated by any organization.
TABLE 2. Molecular epidemiological characteristics of Nei-
sseria gonorrhoeae isolates in Estonia, 2009–2013
NG-MAST
Year
Total2009 2010 2011 2012 2013
ST211 2 2a
ST437 1 1b
ST1241 2 1 1 5 5 14
ST2212 1 1 4b 6c
ST2449 1 1d
ST3611 2 2a
ST4120 1 1b
ST5185 1 1
ST7482e 2 2
ST7483e 2 2
ST7484e 1 1d
ST7485e 1 1 2
ST7486e 1 1
ST7487e 1f 2f 3g
ST7488e 1 1
ST8392 1 1f
ST9900a 2 2
ST9901a 1 1
Total 5 6 5 15 13 44
NG-MAST, Neisseria gonorrhoeae multiantigen sequence type; ST, sequence type.
aAll isolates resistant to ciproﬂoxacin and tetracycline, and producing b-lactamase.
bIncluding isolates with decreased susceptibility (MIC = 0.125 mg/L [11, 18]) or
resistance (MIC >0.125 mg/L) to extended-spectrum cephalosporins, including
resistance to azithromycin (MIC >0.5 mg/L), ciproﬂoxacin (MIC >0.064 mg/L) and
tetracycline (MIC >1 mg/L).
cAll isolates resistant to azithromycin, ciproﬂoxacin and tetracycline.
dIsolates resistant to azithromycin.
eNot previously described sequence types.
fIsolates resistant to tetracycline.
gAll isolates producing b-lactamase.
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identiﬁed. All these three isolates possessed the penA mosaic
allele XXXIV, which has been associated with ST1407 or
closely related STs (genogroup 1407 [15–19]) that have
accounted for most decreased susceptibility or resistance to
extended-spectrum cephalosporins (ESCs) in many European
countries and mainly globally, and resulted in most veriﬁed
ESC treatment failures [4,10–12,15–19]. Moreover, two of
these isolates, assigned as ST2212 and ST4120, also belonged
to this genogroup 1407, which additionally is multidrug
resistant [19]. The remaining isolate, assigned as ST437, has
also been previously associated with decreased ESC suscep-
tibility [15,17–21]. The most prevalent ST (n = 14) in this
study, ST1241, has been previously described in Italy in
N. gonorrhoeae isolated from heterosexual males in 2003–2005
[17]. However, in that study the ST1241 isolates displayed
resistance to ciproﬂoxacin and tetracycline, whereas in this
study all the isolates (n = 14) were susceptible to both these
antimicrobials. This highlights the caution required when using
genotyping, such as NG-MAST, only for prediction and
surveillance of AMR.
In conclusion, it is crucial to continuously follow the spread
of gonococcal strains with multidrug resistance and decreased
susceptibility or resistance to ESCs in Estonia, and implement
quality-assured culture-based surveillance of gonococcal AMR
(ideally also treatment failures) in Estonia.
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